Home » Stocks » ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited (ASLN)

Stock Price: $1.98 USD -0.02 (-1.00%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 75.22M
Revenue (ttm) 3.00M
Net Income (ttm) -47.07M
Shares Out 37.99M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $1.98
Previous Close $2.00
Change ($) -0.02
Change (%) -1.00%
Day's Open 1.99
Day's Range 1.98 - 2.05
Day's Volume 41,071
52-Week Range 0.35 - 8.18

More Stats

Market Cap 75.22M
Enterprise Value 71.67M
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 37.99M
Float 36.90M
EPS (basic) -0.29
EPS (diluted) -0.86
FCF / Share -0.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 45,709
Short Ratio 0.49
Short % of Float n/a
Beta 1.72
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 25.07
PB Ratio 6.05
Revenue 3.00M
Operating Income -45.58M
Net Income -47.07M
Free Cash Flow -25.51M
Net Cash 3.55M
Net Cash / Share 0.09
Gross Margin 2,660.70%
Operating Margin -1,519.30%
Profit Margin -1,568.90%
FCF Margin -850.21%
ROA -41.96%
ROE -408.12%
ROIC -430.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(177.78% upside)
Current: 1.98
Target: 5.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit2.59--11.42
Operating Income-45.58-42.35-39.14-8.70
Net Income-47.07-42.19-39.89-9.05
Shares Outstanding160168168-
Earnings Per Share-0.29-0.28-0.32-0.09
Operating Cash Flow-25.51-39.72-34.48-5.80
Capital Expenditures--23.08-0.30-0.46
Free Cash Flow-25.51-62.81-34.78-6.25
Cash & Equivalents22.2028.9150.5751.74
Total Debt18.6513.979.688.34
Net Cash / Debt3.5514.9340.8943.40
Book Value-1.6830.6235.5141.57
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ASLAN Pharmaceuticals Limited
Country Singapore
CEO Carl Aslan Jason Morton Firth

Stock Information

Ticker Symbol ASLN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ASLN
IPO Date May 4, 2018


ASLAN Pharmaceuticals Limited operates as a clinical-stage oncology and inflammatory disease focused biopharmaceutical company in the United States. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor (HER), inhibitor that targets the human epidermal growth factor receptors HER1, and HER2, as well as gastric cancer. Its Varlitinib completed a pivotal clinical trial for biliary tract cancer. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. Further, the company has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has licensing agreement with Bristol-Myers Squibb, Almirall, CSL Limited, Hyundai Pharm Co., Ltd., and BioGenetics Co. Ltd.; and licensing and research collaboration agreement with Nanyang Technological University. The company was founded in 2010 and is headquartered in Singapore.